BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased MabVax Therapeutics Holdings (“MabVax” or the “Company”) (NASDAQ: MBVX) securities between March 14, 2016 and May 18, 2018, inclusive (the “Class Period”). MabVax investors have until August 3, 2018 to file a lead plaintiff motion.
Investors that suffered losses on their MabVax investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
The Complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) MabVax's internal controls over financial reporting were materially weak and deficient; (2) MabVax had incorrectly calculated and reported beneficial ownership of its shares, and permitted improper influence or control over the Company, and/or its officers and directors by certain shareholders; and, (3) consequently, MabVax's financial statements and Defendants' statements about MabVax's business, operations, and prospects, were materially false and misleading at all relevant times.
If you purchased shares of MabVax during the Class Period, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.